First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: An open-label, single-arm, phase 2 trial Journal Article

Authors: Janjigian, Y. Y.; Maron, S. B.; Chatila, W. K.; Millang, B.; Chavan, S. S.; Alterman, C.; Chou, J. F.; Segal, M. F.; Simmons, M. Z.; Momtaz, P.; Shcherba, M.; Ku, G. Y.; Zervoudakis, A.; Won, E. S.; Kelsen, D. P.; Ilson, D. H.; Nagy, R. J.; Lanman, R. B.; Ptashkin, R. N.; Donoghue, M. T. A.; Capanu, M.; Taylor, B. S.; Solit, D. B.; Schultz, N.; Hechtman, J. F.
Article Title: First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: An open-label, single-arm, phase 2 trial
Abstract: Background: Addition of trastuzumab to first-line chemotherapy improves overall survival in patients with HER2-positive metastatic gastric cancer. We assessed the safety and activity of pembrolizumab in combination with trastuzumab and chemotherapy in first-line HER2-positive metastatic oesophagogastric (gastric, oesophageal, or gastroesophageal junction) cancer. Methods: This study was an investigator-initiated, open-label, non-randomised, single-arm, single centre, phase 2 trial in patients aged 18 years or older with HER2-positive metastatic oesophagogastric cancer. Eligible patients had measurable or evaluable non-measurable disease, Eastern Cooperative Oncology Group performance status of 0, 1, or 2, and left ventricular ejection fraction of at least 53%. Patients were eligible to receive an initial induction cycle of 200 mg flat dose of intravenous pembrolizumab and 8 mg/kg loading dose of intravenous trastuzumab. For subsequent cycles, patients received 130 mg/m2 of intravenous oxaliplatin or 80 mg/m2 of cisplatin on day 1, 850 mg/m2 of oral capecitabine twice a day for 2 weeks followed by 1 week off (or intravenous 5-fluorouracil, 800 mg/m2 per day on days 1–5), and a 200 mg flat dose of intravenous pembrolizumab, and 6 mg/kg of trastuzumab, administered on day 1 of each 3-week cycle. The primary endpoint was 6-month progression-free survival, defined as the proportion of patients alive and free of progression at 6 months, assessed in patients who received at least one dose of trastuzumab and pembrolizumab. The regimen would be considered worthy of further investigation if 26 or more of 37 patients were progression-free at 6 months. This trial is registered with, NCT02954536, and is ongoing, but closed to enrolment. Findings: Between Nov 11, 2016, and Jan 23, 2019, 37 patients were enrolled. At the time of data cutoff on Aug 6, 2019, median follow-up among survivors was 13·0 months (IQR 11·7–23·5). The primary endpoint was achieved; 26 (70%; 95% CI 54–83) of 37 patients were progression-free at 6 months. The most common treatment-related adverse event of any grade was neuropathy, which was reported in 36 (97%) of 37 patients. The most common grade 3 or 4 adverse events were lymphocytopenia (seven [19%] patients with grade 3 and two [5%] with grade 4), grade 3 decreased electrolytes (six [16%] patients), and grade 3 anaemia (four [11%] patients). Serious adverse events occurred in two patients patients (both grade 3 nephritis leading to treatment discontinuation). Four patients discontinued pembrolizumab because of immune-related adverse events. There were no treatment-related deaths. Interpretation: Pembrolizumab can be safely combined with trastuzumab and chemotherapy and has promising activity in HER2-positive metastatic oesophagogastric cancer. A randomised phase 3 clinical trial assessing the efficacy and safety of pembrolizumab versus placebo in combination with trastuzumab and chemotherapy in first-line HER2-positive metastatic oesophagogastric cancer is underway. Funding: Merck & Co. © 2020 Elsevier Ltd
Keywords: adult; clinical article; treatment outcome; aged; survival rate; drug activity; fatigue; paresthesia; cisplatin; fluorouracil; diarrhea; drug efficacy; drug safety; drug withdrawal; capecitabine; follow up; anorexia; metastasis; progression free survival; multiple cycle treatment; phase 2 clinical trial; sensory neuropathy; anemia; nausea; vomiting; epidermal growth factor receptor 2; cohort analysis; cancer survivor; abdominal pain; coughing; hyperglycemia; hypomagnesemia; loading drug dose; lymphocytopenia; pruritus; rash; hypokalemia; hyponatremia; peripheral edema; stomach cancer; colitis; liver disease; open study; hyperbilirubinemia; headache; trastuzumab; oxaliplatin; esophagus cancer; hand foot syndrome; heart left ventricle ejection fraction; dry skin; disease exacerbation; lymphocyte depletion; immunopathology; physical performance; hematologic disease; induction chemotherapy; oral mucositis; electrolyte disturbance; dysgeusia; neutrophilia; body weight disorder; thrombocyte disorder; human; male; female; priority journal; article; pembrolizumab; interstitial nephritis; disease assessment; metastatic esophagogastric cancer; heart failure with reduced ejection fraction
Journal Title: Lancet Oncology
Volume: 21
Issue: 6
ISSN: 1470-2045
Publisher: Elsevier Science, Inc.  
Date Published: 2020-06-01
Start Page: 821
End Page: 831
Language: English
DOI: 10.1016/s1470-2045(20)30169-8
PUBMED: 32437664
PROVIDER: scopus
PMCID: PMC8229851
Notes: Article -- Export Date: 1 July 2020 -- Source: Scopus
Citation Impact
MSK Authors
  1. Joanne Fu-Lou Chou
    236 Chou
  2. David Solit
    629 Solit
  3. Geoffrey Yuyat Ku
    151 Ku
  4. Marinela Capanu
    304 Capanu
  5. Yelena Yuriy Janjigian
    244 Janjigian
  6. David H Ilson
    355 Ilson
  7. David P Kelsen
    480 Kelsen
  8. Barry Stephen Taylor
    226 Taylor
  9. Nikolaus D Schultz
    318 Schultz
  10. Michal F Segal
    13 Segal
  11. Elizabeth Siryeon Won
    34 Won
  12. Jaclyn Frances Hechtman
    196 Hechtman
  13. Parisa   Momtaz
    35 Momtaz
  14. Walid Khaled Chatila
    47 Chatila
  15. Shweta S Chavan
    15 Chavan
  16. Steven Maron
    27 Maron